Rep. Haley Stevens leads challenger Abdul El-Sayed by nearly seven percentage points in the Democratic primary for Michigan’s U.S. Senate seat, according to a July 2026 poll. The race has emerged as a high-stakes test of the party’s direction, highlighting deep ideological divisions over electability and policy in a critical battleground state.
Polling Data and Voter Demographics
A survey conducted by the Glengariff Group for The Detroit News and WDIV-TV shows Rep. Haley Stevens holding 48.2% of support among likely Democratic primary voters, compared to 41.4% for Abdul El-Sayed. The poll, conducted between July 8 and July 11, 2026, carries a margin of error of 4.4 percentage points.
The data reveals a stark split in the Democratic base. Foxnews, Stevens maintains a 22-point lead among non-college-educated voters and a 46-point advantage with Black voters. Conversely, El-Sayed, a former Wayne County Health Department director, leads by seven points among college-educated voters and holds a 12-point edge with white voters.
Ideological Conflict and Party Identity
The Senate primary has become a proxy for a broader national debate within the Democratic Party. Stevens, backed by establishment figures including Sen. Chuck Schumer and retiring Sen. Gary Peters, is positioning herself as the candidate best suited to win the general election against likely Republican nominee Mike Rogers. El-Sayed, endorsed by Sen. Bernie Sanders and Rep. Alexandria Ocasio-Cortez, is running on a progressive platform centered on healthcare reform and anti-corruption measures.
As reported by The Hill, some moderate strategists fear that El-Sayed’s policy positions—specifically his past comments on policing—could alienate the voters necessary to secure a win in November. Matt Bennett, executive vice president of the moderate think tank Third Way, labeled the strategy of running far-left candidates in swing states as extremely dangerous
for the party.
“I want my party to win but I don’t think my party can win by running a candidate like El-Sayed who is so far left, it turns everyone else off. If we lose the general in Michigan, that should send shock signals to everyone that we won’t be able to win a national election in 2028 if we run those kinds of candidates.”
Unnamed Democratic strategist, via The Hill
Progressive Defense and Electability Arguments
Supporters of El-Sayed reject the claim that he is unelectable, pointing to his history of statewide campaigning in Michigan. Joel Payne, a strategist with MoveOn, argued that El-Sayed’s positions on healthcare and the Israel-Gaza war are broadly popular. The guy played lacrosse at the University of Michigan, and he’s running at worst even and, in most cases, more competitive than his opponent with the likely Republican in every general election poll I’ve seen,
Payne said.
The primary field narrowed significantly last week when state Sen. Mallory McMorrow, who had been running in the ideological middle, suspended her campaign. Her exit leaves the contest as a direct confrontation between the party’s two primary wings.
Strategic Stakes for the 2026 Midterms
The primary results will determine who takes on Mike Rogers, who is seeking the seat following the retirement of Gary Peters. While progressives argue that their movement represents the future of the party, moderates emphasize the necessity of winning over moderate voters—a demographic that some analysts argue was critical to President Biden’s success in previous cycles.
As voters prepare for the August 4 primary, the central question remains whether the Democratic base will prioritize a candidate who mirrors their values or one viewed as most capable of securing a victory in the general election.
Find more reporting in our World section.
Keep reading
- Back After Three Months
- Prince Harry and Meghan Markle Granted UK Security Review
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)